Pharmaceuticals News and Research

RSS

Elephantiasis and river blindness: MSU researcher receives $2M for reformulating flubendazole

In an effort to eliminate the tropical diseases elephantiasis and river blindness, a Michigan State University researcher has been awarded $2 million to reformulate an existing drug that could stop the debilitating diseases in their tracks.

5 Feb 2010

Top-line results from Optimer Pharmaceuticals' second fidaxomicin Phase 3 trial in CDI patients

Optimer Pharmaceuticals, Inc. today announced positive top-line results from the second of two pivotal Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI). This study was conducted in approximately 100 clinical sites throughout North America and Europe. The Company plans to use data from this study to support submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2010.

5 Feb 2010

Oxford Finance Corporation announces $25M credit facility to EUSA Pharma

Oxford Finance Corporation today announced that it is the agent and primary lender for a $25 million credit facility provided to EUSA Pharma. MidCap Financial and Silicon Valley Bank are co-lenders in the transaction.

5 Feb 2010

BioMarin announces update on BMN 110 Phase I/II trial for Morquio A Syndrome

BioMarin Pharmaceutical Inc. today announced an update on the Phase I/II trial for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. Preliminary clinical data from the first 24 weeks of the study (12 weeks at 0.1mg/kg and 12 weeks at 1.0 mg/kg) have been evaluated, and BioMarin plans to announce top-line results for the full 36-week study after completion of dosing at 2.0 mg/kg in the second quarter of 2010.

5 Feb 2010

Pfizer, DxS sign agreement to develop a diagnostic test kit for CDX-110 to treat patients with GBM

Pfizer Inc. and DxS (a wholly owned subsidiary of QIAGEN N.V.) today announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM).

5 Feb 2010

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

Paloma Pharmaceuticals, Inc. announced today that it has received acceptance of its IND to enter Phase I studies with Palomid 529 (P529) in patients with age-related macular degeneration (AMD).

5 Feb 2010

PSKW & Associates purchases Triax Media

PSKW & Associates LLC of Edison, New Jersey, which owns the Loyalty Rx Co-pay Card, has purchased Triax Media LLC of Irvine, California. At the same time, PSKW has licensed the purchase to its subsidiary, Centricity Group LLC of Mendham, New Jersey.

5 Feb 2010

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells.

4 Feb 2010

BioMarin Pharmaceutical signs stock purchase agreement to acquire LEAD Therapeutics

BioMarin Pharmaceutical Inc. announced today that it has entered into a stock purchase agreement to acquire LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers.

4 Feb 2010

"Knowledge deficit" about methadone responsible for resulting deaths

In a unique and comprehensive literature review of poisoning deaths involving opioids from 1999 -- 2009, the deaths involving methadone were found to be disproportionately high. Methadone represented less than five percent of all opioid prescriptions but is responsible for a third of the deaths. After four years of investigation, the major underlying cause was found to be fundamental misunderstandings about the properties of the medicine -- a "knowledge deficit" -- especially when converting patients from other opioids.

4 Feb 2010

BioCryst Pharmaceuticals announces fourth-quarter and full-year 2009 financial results

BioCryst Pharmaceuticals, Inc. today announced financial results for the fourth quarter and year ended December 31, 2009.

4 Feb 2010

Sun Pharmaceutical Industries prohibited to purchase additional Taro shares while temporary injunction remains in effect

Taro Pharmaceutical Industries Ltd. today announced that the Supreme Court of the State of Israel (the “Supreme Court”) has ruled that Sun Pharmaceutical Industries Ltd. (“Sun”) may not exercise a warrant to purchase additional Taro shares while a previously ordered temporary injunction remains in effect.

4 Feb 2010

Discussion on IATA Chapter 17 compliance for temperature-sensitive products at 8th Cold Chain Summit

Pharma IQ, a division of IQPC, announces that Kevin O’Donnell Director & CTA of Tegrant Corporation and Chair of IATA’s Time & Temperature Task Force will discuss compliance with IATA’s revised Chapter 17 at the 8th Cold Chain Management and Temperature Control Summit.

From IQPC Ltd 4 Feb 2010

Akela announces the outcomes of two legal cases involving former employees

Akela a leader in the development of therapeutics for the treatment of pain and its wholly owned subsidiary, PharmaForm, a leader in the contract pharmaceutical development and manufacturing business, today announced the outcomes of two legal cases involving former employees.

4 Feb 2010

First annual Translational Regenerative Medicine Forum in Winston-Salem

The Regenerative Medicine Foundation today announced the first annual Translational Regenerative Medicine Forum to be held April 6-8, 2010 at the Benton Convention Center in Winston-Salem.

4 Feb 2010

New Hanover Regional Medical Center renews supply chain agreement with Broadlane

Broadlane, the leading end-to-end cost-management partner for healthcare providers, announced today that New Hanover Regional Medical Center, in Wilmington, North Carolina, has renewed its supply chain relationship with Broadlane for another five years. New Hanover will continue to access Broadlane’s unparalleled national contract portfolio of consumable supplies, equipment, pharmaceuticals and purchased services to help manage approximately $130 million in annual supply spend.

4 Feb 2010

Verizon Business to provide secure private IP network for Eurofins Scientific

Under a three-year extension of an existing relationship, Verizon Business will securely connect 16 key Eurofins laboratories and research centers in Europe, Asia and the U.S. with the company's global customer base.

4 Feb 2010

EUCODIS Bioscience to utilize EUR 2M capital injection for adding enzyme families and development of international markets

EUCODIS Bioscience, a company providing customized enzymes to the pharmaceutical, chemical, and other industries, announced today that it has received a cash injection of EUR 2 million from existing shareholders.

4 Feb 2010

Ipsen launches Decapeptyl LP 22.5 mg in France

Ipsen, an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.

4 Feb 2010

Shire's clinical study results for treatment of Gaucher disease to be presented at LDN World Symposium

Shire plc, the global specialty biopharmaceutical company, today announced that data from one of three Phase III clinical trials for velaglucerase alfa, the company's enzyme replacement therapy (ERT) in development for the treatment of Type 1 Gaucher disease, will be presented at the Lysosomal Disease Network (LDN) World Symposium, February 10-12, 2010 in Miami, Florida.

4 Feb 2010

Pharmaceuticals News and Research

Elephantiasis and river blindness: MSU researcher receives $2M for reformulating flubendazole

Top-line results from Optimer Pharmaceuticals' second fidaxomicin Phase 3 trial in CDI patients

Oxford Finance Corporation announces $25M credit facility to EUSA Pharma

BioMarin announces update on BMN 110 Phase I/II trial for Morquio A Syndrome

Pfizer, DxS sign agreement to develop a diagnostic test kit for CDX-110 to treat patients with GBM

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

PSKW & Associates purchases Triax Media

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

BioMarin Pharmaceutical signs stock purchase agreement to acquire LEAD Therapeutics

"Knowledge deficit" about methadone responsible for resulting deaths

BioCryst Pharmaceuticals announces fourth-quarter and full-year 2009 financial results

Sun Pharmaceutical Industries prohibited to purchase additional Taro shares while temporary injunction remains in effect

Discussion on IATA Chapter 17 compliance for temperature-sensitive products at 8th Cold Chain Summit

Akela announces the outcomes of two legal cases involving former employees

First annual Translational Regenerative Medicine Forum in Winston-Salem

New Hanover Regional Medical Center renews supply chain agreement with Broadlane

Verizon Business to provide secure private IP network for Eurofins Scientific

EUCODIS Bioscience to utilize EUR 2M capital injection for adding enzyme families and development of international markets

Ipsen launches Decapeptyl LP 22.5 mg in France

Shire's clinical study results for treatment of Gaucher disease to be presented at LDN World Symposium

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence